Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A Randomized Controlled Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
CONTEXT: Ziconotide (formerly SNX-111) selectively blocks N-type voltage-sensitive calcium channels and may be effective in patients with pain that is refractory to opioid therapy or those with intolerable opioid-related adverse effects. OBJECTIVE: To assess the safety and efficacy of intrathecal ziconotide in patients with pain that is refractory to conventional treatment. DESIGN, SETTING, AND PATIENTS: Double-blind, placebo-controlled, randomized trial conducted from March 12, 1996, to July 11, 1998, at 32 study centers in the United States, Australia, and the Netherlands. Patients were 111 individuals ages 24 to 85 years with cancer or AIDS and a mean Visual Analog Scale of Pain Intensity (VASPI) score of 50 mm or greater. Patients were randomly assigned in a 2:1 ratio to receive ziconotide or placebo treatment. INTERVENTIONS: Intrathecal ziconotide was titrated over 5 to 6 days, followed by a 5-day maintenance phase for responders and crossover of nonresponders to the opposite treatment group. MAIN OUTCOME MEASURE: Mean percentage change in VASPI score from baseline to the end of the initial titration period. RESULTS: Of the evaluable population, 67 (98.5%) of 68 patients receiving ziconotide and 38 (95%) of 40 patients receiving placebo were taking opioids at baseline (median morphine equivalent dosage of 300 mg/d for the ziconotide group and 600 mg/d for the placebo group; P =.63, based on mean values), and 36 had used intrathecal morphine. Mean (SD) VASPI scores were 73.6 (1.8) mm in the ziconotide group and 77.9 (2.3) mm in the placebo group (P =.18). Mean VASPI scores improved 53.1% (95% confidence interval [CI], 44.0%-62.2%) in the ziconotide group and 18.1% (95% CI, 4.8%-31.4%) in the placebo group (P<.001), with no loss of efficacy of ziconotide in the maintenance phase. Pain relief was moderate to complete in 52.9% of patients in the ziconotide group compared with 17.5% in the placebo group (P<.001). Five patients receiving ziconotide achieved complete pain relief, and 50.0% of patients receiving ziconotide responded to therapy compared with 17.5% of those receiving placebo (P =.001). CONCLUSION: Intrathecal ziconotide provided clinically and statistically significant analgesia in patients with pain from cancer or AIDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zech, D. F. J., Grond, S., Lynch, J., Hertel, D., & Lehmann, K. A. (1995) · Pain · doi:10.1016/0304-3959(95)00017-m · Cited by 1,015
Peptide Neurotoxins from Fish-Hunting Cone Snails
Olivera, B. M., Gray, W. R., Zeikus, R., McIntosh, J. M., Varga, J., Rivier, J., de Santos, V., & Cruz, L. J. (1985) · Science · doi:10.1126/science.4071055 · Cited by 747
Antagonists of Neuronal Calcium Channels: Structure, Function, and Therapeutic Implications
Miljanich, G. P., & Ramachandran, J. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.003423 · Cited by 323
The undertreatment of pain in ambulatory AIDS patients
Breitbart, W., Rosenfeld, B. D., Passik, S. D., McDonald, M. V., Thaler, H., & Portenoy, R. K. (1996) · Pain · doi:10.1016/0304-3959(95)00217-0 · Cited by 293
Bowersox, S. S., Gadbois, T., Singh, T., Pettus, M., Wang, Y. X., & Luther, R. R. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21283-6 · Cited by 274
Self-citationMcGuire, D., Bowersox, S. S., FELLMANN, J. D., & Luther, R. R. (1997) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199709000-00019 · Cited by 82
Self-citationMarcil, W. M. (1995) · American Journal of Occupational Therapy · doi:10.5014/ajot.49.10.1082b · Cited by 45
Ziconotide: A new pharmacological class of drug for the management of pain
Mathur, V. S. (2000) · Seminars in Anesthesia Perioperative Medicine and Pain · doi:10.1053/sa.2000.6787 · Cited by 36
Cited by
Zamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
Newman, D. J., & Cragg, G. M. (2004) · Journal of Natural Products · doi:10.1021/np040031y · Cited by 759
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Targeting voltage-gated calcium channels in neurological and psychiatric diseases
Zamponi, G. W. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.5 · Cited by 368
The glymphatic system: Current understanding and modeling
Bohr, T., Hjorth, P. G., Holst, S. C., Hrabětová, S., Kiviniemi, V., Lilius, T., Lundgaard, I., Mardal, K.-A., Martens, E. A., Mori, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104987 · Cited by 368
Deer, T. R., Pope, J. E., Hayek, S. M., Bux, A., Buchser, E., Eldabe, S., De Andrés, J. A., Erdek, M., Patin, D., Grider, J. S., et al. (2017) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12538 · Cited by 358
Self-citationZiconotide for treatment of severe chronic pain
Schmidtko, A., Lötsch, J., Freynhagen, R., & Geisslinger, G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60354-6 · Cited by 356
Calcium-Permeable Ion Channels in Pain Signaling
Bourinet, E., Altier, C., Hildebrand, M. E., Trang, T., Salter, M. W., & Zamponi, G. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00023.2013 · Cited by 337
Ziconotide: a review of its pharmacology and use in the treatment of pain
McGivern, J. G. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.1.69 · Cited by 310
Rauck, R. L., Wallace, M. S., Leong, M. S., MineHart, M., Webster, L. R., Charapata, S. G., Abraham, J. E., Buffington, D. E., Ellis, D., Kartzinel, R., et al. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.10.003 · Cited by 306
Self-citationConus Peptides: Biodiversity-based Discovery and Exogenomics
Olivera, B. M. (2006) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84029-2 · Cited by 302
McDowell II, G. C., & Pope, J. E. (2016) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12392 · Cited by 57
Metadata
- Authors
- Staats, P. S., Yearwood, T., Charapata, S. G., Presley, R. W., Wallace, M. S., Byas-Smith, M., Fisher, R., Bryce, D. A., Mangieri, E. A., Luther, R. R., Mayo, M., McGuire, D., & Ellis, D.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-01-07
- Volume
- 291
- Issue
- 1
- Pages
- 63
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2151024126
- Cited by
- 654
- References
- 8
- FWCI
- 46.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.